secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001437749-25-014909
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Genprex enters new sponsored research agreement with University of Pittsburgh for GPX-002 diabetes gene therapy
--------------------------------------------------------------------------------

- New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.
- Preclinical T1D data showed statistically significant decreases in insulin requirements and increases in c-peptide levels.
- GPX-002 uses adeno-associated virus vector with Pdx1 and MafA genes delivered via pancreatic duct.
- In T1D, GPX-002 aims to transform alpha cells into functional beta-like cells to evade immune system.
- In T2D, GPX-002 is believed to rejuvenate exhausted beta cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/0001437749-25-014909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/gnpx20250506_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer